Skip to main
HSCS
HSCS logo

HSCS Stock Forecast & Price Target

HSCS Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

HeartSciences Inc. has raised its FY26 EPS estimate to $(4.17) from a previous $(8.63), indicating improved financial projections driven by a higher share count. The upcoming approval of the MyoVista device, alongside the rollout of the MyoVista Insights cloud software platform, is expected to significantly enhance the company’s market presence and revenue potential. Additionally, the anticipated FDA approval of its first diagnostic algorithm by the first half of 2026 further underscores the substantial growth opportunities that lie ahead for HeartSciences.

Bears say

HeartSciences Inc. faces significant challenges that contribute to a negative outlook for its stock, primarily due to balance sheet and liquidity risks, as well as the potential failure of its product candidates to prove safety and efficacy during clinical trials. The company's fiscal year 2026 revenue estimates have drastically decreased from $1.2 million to $0.1 million, largely due to delays in obtaining regulatory approvals from the FDA. Additionally, the company's ability to commercialize its products and secure suitable reimbursement in a competitive healthcare landscape poses further risks, compounded by changing macroeconomic conditions and shifting investor sentiment towards healthcare stocks.

HSCS has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Heart Test Laboratories Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Heart Test Laboratories Inc (HSCS) Forecast

Analysts have given HSCS a Strong Buy based on their latest research and market trends.

According to 2 analysts, HSCS has a Strong Buy consensus rating as of Dec 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $10.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $10.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Heart Test Laboratories Inc (HSCS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.